SYSTEMIC INFLAMMATION, IMMUNE SYSTEM, LIPID PROFILE, AND ELECTROLYTE STATUS IN PATIENTS WITH ATRIAL FIBRILLATION AFTER COVID-19

Authors:

Abstract:

Atrial fibrillation is the most common form of arrhythmia. Associated with significant morbidity and mortality in patients after suffering from COVID-19. The main group was formed of 116 people (64.8 %) with atrial fibrillation who suffered from a coronavirus infection. Control group 1 – 49 patients with atrial fibrillation who had no history of COVID-19 infection. Control group 2 – 22 patients with extrasystole who underwent COVID-19 but did not develop AF. Systemic inflammation, which occurs as a result of CI, provokes the appearance of de novo atrial fibrillation and worsening of the course of an already existing arrhythmia. Accompanied by an increase in the level of the N-terminal fragment of the brain natriuretic peptide precursor. There was no significant difference between the studied groups in the indicators of the level of electrolytes and lipoptotheids.

Keywords:

arrhythmia atrial fibrillation coronavirus infection inflammation lipids heart failure

References:

1. Ali SA, Baloch M, Ahmed N, Ali AA, Iqbal A. The outbreak of Coronavirus Disease 2019 (COVID-19) –An emerging global health threat. J Infect Pub Health. 2020; 13(1) :644–646. doi: 10.1016/j.jiph.2020.02.033.
2. Changaripour S, Sarvazad H, Barghi M, Sajadi E, Sadeghian MH, Roozbahani NE. Lipid profile changes in patients with COVID-19 referred to medical centers in Kermanshah, Iran; a case-control study. J Int Med Res. 2022; 50(2) :30–99. doi: 10.1177/03000605221078699.
3. Chen J, Wang Y, Wang J, Chen L, Luo Q, Wang B, et.al. Coronavirus disease 2019 death prediction by electrocardiographic abnormalities and elevated D-dimer levels. Front Cardiovasc Med. 2022; 9(1): 83–94. doi: 10.3389/fcvm.2022.948347.
4. Donniacuo M, De Angelis A, Rafaniello C, Cianflone E, Paolisso P, Torella D, et.al. COVID-19 and atrial fibrillation: Intercepting lines. Front Cardiovasc Med. 2023; 10(1): 1093053. doi: 10.3389/fcvm.2023.1093053.
5. Gawałko M, Kapłon-Cieślicka A, Hohl M, Dobrev D, Linz D. COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications. Int J Cardiol Heart Vasc. 2020; 30:100631. doi: 10.1016/j.ijcha.2020.100631.
6. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et. al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal. 2021; 42(5):373–498. doi.org/10.1093/eurheartj/ehaa612.
7. Kaufmann CC, Ahmed A, Burger AL, Muthspiel M, Jäger B, Wojta J, et. al. Biomarkers Associated with Cardiovascular Disease in COVID-19. Cells. 2022; 11(6) :922. doi: 10.3390/cells11060922.
8. Lehmann A, Prosch H, Zehetmayer S, Gysan MR, Bernitzky D, Vonbank K, et. al. Impact of persistent D-dimer elevation following recovery from COVID-19. PLoS One. 2021; 16(10) :0258351. doi: 10.1371/journal.pone.0258351. (18).
9. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et. al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi: 10.1093/eurheartj/ehab368.
10. Pranata R, Huang I, Lukito AA, Raharjo SB. Elevated N-terminal pro-brain natriuretic peptide is associated with increased mortality in patients with COVID-19: systematic review and meta-analysis. Postgrad Med J. 2020; 96(1137) :387–391. doi: 10.1136/postgradmedj-2020-137884.
11. Plaut S. “Long COVID-19” and viral “fibromyalgianess”: Suggesting a mechanistic role for fascial myofibroblasts (Nineveh, the shadow is in the fascia). Front Med (Lausanne). 2023; 10:952278. doi: 10.3389/fmed.2023.952278.
12. Sano T, Matsumoto S, Ikeda T, Kuroda S, Kitai T, Yonetsu T. New-Onset Atrial Fibrillation in Patients with Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease – Insights From the CLAVIS-COVID Registry. Circulation Journal. 2022; 86 (8):1237–1244. doi.org/10.1253/circj.CJ-21-0911(8)
13. Serafino Fazio. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ 2022; 377:069590 doi: https://doi.org/10.1136/bmj-2021-069590 (17)
14. Sychov OS, Stasyshena OV, Mikhalieva TV, Torbas OO, Husarchuk AG. Influence og the transmitted infection of COVID-19 on the prevalence and course of atrial fibrillation in hospitalized patients. World of Medicine and Biology. 2023; 3(85) :171–174. doi:10.26724/2079-8334-2023-3-85-171-174
15. Yarmola TI, Gutsalenko OO, Tkachenko LA, Katerenchuk IP, Kostrikova UA, Pustovoyt HL, Talash VV, Tsyganenko IV. Microscopic Polyangiitis is a “Masquerade Ball” in Modern Realities: A Literature Review. J Urol Nephrol. 2023; 8 (4): 000248. doi: 10.23880/oajun-16000248

Publication:

«World of Medicine and Biology» Vol. 20 No. 87 (2024) , с. 166-171
УДК 616.002.1:616.12-008.46-008.313:612.397:616.988

DOI:

https://doi.org/10.26724/2079-8334-2024-1-87-166-171